News on MUC1 from BioPortfolio.com http://www.BioPortfolio.com Consolidated MUC1 news from BioPortfolio.com Wed, 10 Feb 2010 01:30:21 GMT en Breast Cancer: Investigators at Harvard University, Dana-Farber Cancer Institute have published new data on breast cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3932935&HITNO=0&MSIZE=8&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=MUC1&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3932935&THISHREF=http://c.moreover.com/click/here.pl%3fz2481419226%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3932935&HITNO=0&MSIZE=8&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=MUC1&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3932935&THISHREF=http://c.moreover.com/click/here.pl%3fz2481419226%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNewsRX: Fibroadenoma: Studies from University Autonoma Benito Juarez of Oaxaca update current data on fibroadenomahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3905487&HITNO=1&MSIZE=8&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=MUC1&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3905487&THISHREF=http://c.moreover.com/click/here.pl%3fz2466301773%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3905487&HITNO=1&MSIZE=8&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=MUC1&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3905487&THISHREF=http://c.moreover.com/click/here.pl%3fz2466301773%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNewsRX: Non-Small-Cell Lung Cancer (NSCLC) - Drug Pipeline Analysis And Market Forecasts To 2015 - New Report Publishehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3804456&HITNO=2&MSIZE=8&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=MUC1&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3804456&THISHREF=http://c.moreover.com/click/here.pl%3fz2410891238%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3804456&HITNO=2&MSIZE=8&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=MUC1&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3804456&THISHREF=http://c.moreover.com/click/here.pl%3fz2410891238%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comOfficialSpin: Oncothyreon announces initiation of Phase 3 trial of Stimuvax in Asian patients with NSCLChttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3762662&HITNO=3&MSIZE=8&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=MUC1&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3762662&THISHREF=http://c.moreover.com/click/here.pl%3fz2392005746%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3762662&HITNO=3&MSIZE=8&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=MUC1&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3762662&THISHREF=http://c.moreover.com/click/here.pl%3fz2392005746%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR Newswire via Yahoo!: Clarient gets exclusive right to test to identify MUCI protein from Minerva Biotechhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3721266&HITNO=4&MSIZE=8&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=MUC1&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3721266&THISHREF=http://c.moreover.com/click/here.pl%3fz2372935838%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3721266&HITNO=4&MSIZE=8&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=MUC1&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3721266&THISHREF=http://c.moreover.com/click/here.pl%3fz2372935838%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmaBiz: Clarient Granted Exclusive License to Commercialize Cancer Biomarker by Minerva Biotechnologieshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3714547&HITNO=5&MSIZE=8&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=MUC1&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3714547&THISHREF=http://c.moreover.com/click/here.pl%3fz2370423674%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3714547&HITNO=5&MSIZE=8&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=MUC1&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3714547&THISHREF=http://c.moreover.com/click/here.pl%3fz2370423674%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Clarient Granted Exclusive License to Commercialize Cancer Biomarker by Minerva Biotechnologieshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3706356&HITNO=6&MSIZE=8&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=MUC1&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3706356&THISHREF=http://c.moreover.com/click/here.pl%3fz2367337934%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3706356&HITNO=6&MSIZE=8&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=MUC1&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3706356&THISHREF=http://c.moreover.com/click/here.pl%3fz2367337934%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR Newswire via Yahoo!: Clarient Granted Exclusive License to Commercialize Cancer Biomarker by Minerva Biotechnologieshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3706361&HITNO=7&MSIZE=8&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=MUC1&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3706361&THISHREF=http://c.moreover.com/click/here.pl%3fz2367339210%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3706361&HITNO=7&MSIZE=8&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=MUC1&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3706361&THISHREF=http://c.moreover.com/click/here.pl%3fz2367339210%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR Newswire: